A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

87 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-08-11

Study Completion Date

2015-05-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial is conducted in Europe. The aim of the trial is to investigate the effects of semaglutide on ß-cell function in subjects with type 2 diabetes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects

NCT02060266

Diabetes Healthy

COMPLETED PHASE1

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes

NCT01686945

Diabetes Diabetes Mellitus, Type 2 Healthy

COMPLETED PHASE1

A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes

NCT04032197

Diabetes Mellitus, Type 2

COMPLETED PHASE1

Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.

NCT02877355

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE1

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

NCT03914326

Diabetes Mellitus, Type 2

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Semaglutide

Total of 12 visits

Group Type EXPERIMENTAL

semaglutide

Intervention Type DRUG

Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.

Placebo

Total of 12 visits

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.

Healthy subjects

Total of 2 visits

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

semaglutide

Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.

Intervention Type DRUG

placebo

Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: 18-64 years (both inclusive) at the time of signing the informed consent
* For subjects with type 2 diabetes:
* Male and female subjects diagnosed with type 2 diabetes
* Treated with diet and exercise and/or metformin monotherapy. Metformin dose should be unchanged in a period of 30 days prior to screening
* Body Mass Index (BMI) between 20.0-35.0 kg/m\^2 (both inclusive)
* Glycosylated haemoglobin (HbA1c) between 6.5-9.0 % (both inclusive)
* For healthy control group for graded glucose infusion:
* Healthy male and female subjects
* BMI between 24.0-32.0 kg/m\^2 (both inclusive)
* HbA1c less than 6.5 %

Exclusion Criteria

* Female who is pregnant, breast-feeding or intends to become pregnant or is of child bearing potential and not using an adequate contraceptive method. Women of child bearing potential must use an effective method of birth control for the duration of the trial and for subjects with type 2 diabetes for 5 weeks following the last dose of semaglutide. Only highly effective methods of birth control are accepted (i.e. one that results in less than 1% per year failure rate when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices), or sexual abstinence or vasectomised partner
* Any clinically significant disease history, in the opinion of the investigator, or systemic or organ disease including: cardiac, pulmonary, gastrointestinal, hepatic, neurologic, renal, genitourinary and endocrine, dermatologic or hematologic
* Use of any prescription or non-prescription medication which could interfere with trial pharmacokinetic or pharmacodynamic results, as judged by the investigator or specifically: a) current treatment with systemic (oral or i.v.) corticosteroids, non-selective betablockers, b) thyroid hormones are not allowed unless the use of these have been stable during the past 2 month prior to screening
* History of drug/chemical substance abuse within 1 year prior to screening, or a positive result in the urine drug test
* History of alcohol abuse within 1 year prior to screening, or a positive result in the alcohol breath test
* Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)
* Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period

Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No